- Anebulo Pharma (NASDAQ:ANEB) said on Thursday that it expects to release topline data from one part of its ongoing Phase 2 study of ANEB-001 to potentially treat acute cannabinoid intoxication (ACI) on July 5.
- The company said the results of the study, which was conducted in sixty healthy subjects, challenged with THC, will be used to design the next step forward in the trial for ANEB-001 as a potential treatment of ACI.
Anebulo Pharma to announce data from phase 2 trial for acute cannabinoid intoxication on July 5
Recommended For You
More Trending News
About ANEB Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| ANEB | - | - |
| Anebulo Pharmaceuticals, Inc. | ||